Atrial fibrillation and anticoagulation in HD

Bottom line

• No randomized trial has yet shown that anticoagulating a hemodialysis patient with atrial fibrillation (AF) prevents strokes. The only completed trial with a no-anticoagulation arm, SAFE-D, was a 151-patient feasibility pilot ¹. AVKDIAL was terminated at 50 patients with no results. DANWARD, SACK, and VISIONAIRE are recruiting, and SAFE-D2 had not opened as of 26 September 2026 ².
• Bleeding outnumbers stroke roughly tenfold. In RENAL-AF, 1-year major or clinically relevant bleeding was 32% on apixaban and 26% on warfarin, against 3.0% and 3.3% for stroke or systemic embolism ³. Circuit heparin given on top of an oral anticoagulant is the dialysis-specific lever: in a 10-patient randomized crossover trial, none of 40 sessions without added circuit anticoagulation ended early ⁴.
• Who to treat is a graded judgment, not a score threshold. A prior ischemic stroke or transient ischemic attack (TIA) favors anticoagulation (grade 2C). Without a prior stroke the decision is equipoise, and an informed decline is a valid choice (2C).
• If you anticoagulate, apixaban is preferred over warfarin (2B). The two apixaban trials against a vitamin K antagonist found no significant difference either way; AXADIA-AFNET 8, funded by Bristol Myers Squibb and Pfizer, reported a safety HR of 0.93 and did not meet noninferiority ^3,5. Warfarin in dialysis runs a time in therapeutic range of 44–58% ^1,3,5, is linked to calciphylaxis ^6,7,8, and bleeds more than apixaban in observational data ^9,10.
• The apixaban dose is genuine equipoise (2C). The FDA label gives 5 mg twice daily unless the patient is 80 or older or weighs 60 kg or less ¹¹. At steady state on hemodialysis, 2.5 mg twice daily reproduces the exposure of 5 mg in normal kidney function, and 5 mg overshoots it ¹². No trial has compared the two doses.
• Statins: no new randomized outcome trial of a lipid-lowering drug in dialysis has appeared. A target-trial emulation and cohort data report lower mortality with statins, strongest in established atherosclerotic disease, which supports the secondary-prevention carve-out (2C) without changing the advice against starting a statin for primary prevention ^13,14,15.

Grades follow the KDIGO convention used in the source review: 1 recommend, 2 suggest; A (high) to D (very low) quality of evidence.

1. How common, and how dangerous

1.1 Prevalence

A 2012 systematic review of 25 studies put AF prevalence at 11.6% and incidence at 2.7 per 100 patient-years in kidney failure ¹⁶; in DOPPS, 12.5% of 17,513 randomly sampled hemodialysis patients had AF at enrollment ¹⁷. Implantable loop recorders detected AF in 41% of 66 patients over six months ¹⁸. The KDIGO controversies conference summarized the range as 15–40% ¹⁹.

1.2 Stroke risk: higher, but is AF the reason?

In observational data, stroke ran at 5.2 versus 1.9 per 100 patient-years in dialysis patients with and without AF ¹⁶, and kidney replacement therapy carried a stroke or thromboembolism HR of 1.83 (95% CI 1.57–2.14) among Danish AF patients ²¹. An Italian cohort of 476, by contrast, found AF associated with death and not with stroke ²². The 2023 ACC/AHA/ACCP/HRS guideline gives three reasons the link looks weaker in dialysis: the competing risk of death, undiagnosed AF among supposedly AF-free comparators, and the heparin patients receive three times a week ²³.

1.3 Bleeding risk

In more than 38,000 DOPPS and PDOPPS patients, hospitalization or death from bleeding occurred at 4.5 per 100 person-years on hemodialysis; gastrointestinal bleeding was the commonest cause, and rates roughly doubled in patients with AF or other cardiovascular disease ²⁴. Crude major-bleeding rates were 8.6 per 100 patient-years with an oral anticoagulant, 5.6 with an antiplatelet agent, and 4.1 with neither ²⁵.

1.4 Why the risk scores fall short

CHA₂DS₂-VASc and HAS-BLED were built in populations that excluded dialysis. A 2026 meta-analysis found pooled c-statistics of 0.70 for CHA₂DS₂-VASc predicting ischemic stroke in dialysis but only 0.55 for HAS-BLED predicting bleeding ²⁶. HAS-BLED awards a point for dialysis itself ²³, and the dialysis-specific BLEED-HD score did better (c-statistic 0.65 vs 0.59) ²⁷. The larger problem is the threshold: general-population cut-offs do not identify which dialysis patients gain from anticoagulation ²⁸, and untreated patients in an Italian cohort had fewer thromboembolic events than CHA₂DS₂-VASc predicted (4.9 vs 8.4 per 100 patient-years) ²⁰. The UK Kidney Association (UKKA) suggests the scores not be used in isolation (2D) ²⁹.

1.5 What practice looks like

Only 24.3% of 82,389 US hemodialysis patients with newly diagnosed AF started an oral anticoagulant within 90 days between 2007 and 2020 (34.1% in 2020), with Black, Asian, and Hispanic patients started less often than White patients ³⁰. Only 57% of DOPPS patients on an anticoagulant at baseline were still taking one at 36 months ²⁵.

2. Should we anticoagulate at all?

2.1 Observational evidence: two decades of contradiction

Every observational comparison of anticoagulation against none is confounded by indication: patients who receive a blood thinner were judged healthy, adherent, and at low enough bleeding risk to receive it.

Five meta-analyses of 15 to 42 studies each tell the same split story. None found a consistent reduction in stroke with warfarin or a DOAC against no anticoagulation ^{39,40,41,42,43}. Warfarin increased hemorrhagic stroke (HR 1.49, 1.03–1.94) ³⁹ and bleeding (HR 1.31–1.47) ^40,41. Only apixaban 5 mg twice daily was associated with lower mortality (HR 0.67, 0.49–0.92) ⁴², a signal that rests on confounded dose selection (section 3.2).

2.2 Randomized trials of anticoagulation versus none (status as of 26 September 2026)

3. Which agent: apixaban, warfarin, and the rest

3.1 Randomized trials of a DOAC against a vitamin K antagonist

All three trials were small and open label. They rule out a large difference; they do not prove equivalence.

Pooled, the three trials show no difference against warfarin in the efficacy composite (RR 0.79, 0.45–1.37) or the safety composite (RR 0.81, 0.52–1.27) ⁴⁷. Adding nine observational studies (31,238 patients), DOACs were associated with less major bleeding (RR 0.68), gastrointestinal bleeding (RR 0.74), and hemorrhagic stroke (RR 0.23), with no difference in ischemic stroke or death ⁴⁸. In USRDS data, apixaban versus warfarin carried a major-bleeding HR of 0.72 (0.59–0.87), about 3 fewer major bleeds per 100 patient-years ⁹; five observational studies pooled gave a major-bleeding OR of 0.51 ¹⁰.

3.2 Apixaban 5 mg or 2.5 mg twice daily

The label. The FDA label reduces the dose to 2.5 mg twice daily when two of age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or more are present. Every dialysis patient meets the creatinine criterion, so on hemodialysis the label gives 2.5 mg if age 80 or older or weight 60 kg or less, and 5 mg otherwise. The label states that its efficacy and safety studies did not enroll patients on dialysis and that the dialysis recommendation rests on pharmacokinetic data ¹¹.

The pharmacology. The label is based on a single 5 mg dose in 8 hemodialysis patients ⁴⁹. At steady state in 7 hemodialysis patients, 2.5 mg twice daily approximated standard exposure, a dialysis session removed only 4%, and 5 mg produced AUC and trough levels above the 90th percentile for 5 mg in preserved kidney function; the authors concluded 5 mg should be avoided ¹².

The outcomes. All observational, with the dose chosen by clinicians. In USRDS data, 5 mg versus 2.5 mg was associated with lower stroke or embolism (HR 0.61) and death (HR 0.64) without more bleeding, but the patients given 5 mg were those judged robust enough ⁹. In another analysis of the same data source, the 5 mg subgroup did worse than no anticoagulation for both stroke and fatal or intracranial bleeding ³⁷. In CKD stages 4–5, largely non-dialysis, 5 mg bled more (subdistribution HR 1.63) with no difference in stroke or death ⁵⁰.

Expert bodies. The KDIGO controversies conference suggested considering 2.5 mg twice daily in CKD G5 and G5D until clinical safety data are available ¹⁹. The UKKA suggests apixaban 2.5 mg twice daily or a vitamin K antagonist (2C) ²⁹. The ACC/AHA guideline calls for “an evidence-based dose of apixaban” and cites the steady-state data favoring 2.5 mg ²³.

3.3 Rivaroxaban, dabigatran, and edoxaban

• Dabigatran: avoid. It depends on kidney excretion and is substantially removed by dialysis ²³. In 29,977 US hemodialysis patients, dabigatran starters had more hospitalization or death from bleeding than warfarin starters (rate ratio 1.48, 1.21–1.81) ⁵².
• Rivaroxaban: one dialysis RCT, at 10 mg only. At full dose, starters bled more than warfarin starters (rate ratio 1.38) ⁵². A 10 mg dose in anuric hemodialysis patients matched the exposure of 20 mg in healthy volunteers ⁵³, and 10 mg is what Valkyrie tested ⁴⁶. KDIGO notes that the US label’s 15 mg dialysis dose rests on pharmacokinetics alone ¹⁹; 10 mg daily for AF is off-label in the United States.
• Edoxaban: not outside a trial. Dialysis removes little of it ⁵⁴, but there are no dialysis outcome data, and KDIGO lists it as not recommended below 15 mL/min ¹⁹.

3.4 Warfarin-specific harms

Poor INR control. Time in therapeutic range (TTR) was 44% in RENAL-AF ³, 50.7% in AXADIA-AFNET 8 ⁵, 58% in SAFE-D ¹, and 49.2% in a Canadian unit ⁵⁵; in US Veterans Affairs data only 21% of dialysis patients reached a TTR of 60% or more ⁵⁶. Warfarin users with no INR measured in the dialysis facility during the first 90 days had the highest stroke risk (HR 2.79, 1.65–4.70) ³¹.

Calciphylaxis. Vitamin K antagonists inhibit carboxylation of matrix Gla protein, a calcification inhibitor ⁴⁴. Warfarin carried an OR of 11.4 for biopsy-confirmed calciphylaxis in a Japanese case-control study ⁶, and 52% of 253 cases in a German registry had received a vitamin K antagonist ⁸. The UKKA treats established calciphylaxis as a contraindication ²⁹. Imaging calcification is a weaker argument: Valkyrie found no difference in calcification progression over 18 months between patients kept on a vitamin K antagonist and those switched to rivaroxaban ⁵⁷.

When warfarin is still the right drug. Mechanical heart valves and moderate-to-severe rheumatic mitral stenosis, which DOAC trials excluded. For a patient on the deceased-donor transplant waiting list, the UKKA suggests a vitamin K antagonist because it can be reversed when an organ is offered (2D) ²⁹.

4. Left atrial appendage occlusion

The extrapolated evidence. Across four general-population RCTs (3,116 patients), left atrial appendage occlusion (LAAO) versus oral anticoagulation reduced all-cause death (RR 0.78) and nonprocedural bleeding, with no difference in stroke ⁵⁸. CHAMPION-AF 2026 (RCT, 3,000 patients, funded by Boston Scientific) reported 3-year nonprocedural bleeding of 10.9% versus 19.0% (ARR 8.1%, NNT approximately 12) with a noninferior efficacy composite ⁵⁹. None of these trials reported dialysis results, and PRAGUE-17 excluded a creatinine clearance below 30 mL/min ²⁰.

Dialysis observational data. An Italian prospective cohort reported thromboembolism HRs of 0.19 versus warfarin and 0.16 versus no anticoagulation ⁶⁰. In USRDS data, LAAO versus anticoagulation was associated with less recurrent bleeding (HR 0.74) but not less stroke after adjustment (HR 1.18, 0.76–1.81) ⁶¹. The procedure itself is riskier with kidney disease (in-hospital mortality OR 2.76) ⁶². Nearly half of post-LAAO bleeding in the Italian cohort occurred in the first 3 months, on dual antiplatelet therapy ²⁰.

The Italian Society of Nephrology (2026) notes that no RCT has tested LAAO in hemodialysis and that peri-procedural complications are higher ⁶⁴.

5. What the guidelines say

6. Practical hemodialysis issues

6.1 Circuit heparin in a patient already anticoagulated

A standard heparin bolus and infusion doubles up in a therapeutically anticoagulated patient. In the only randomized data, Krummel and colleagues gave 10 hemodialysis patients on long-term oral anticoagulation four sessions each, with or without enoxaparin, in a crossover design: none of the 40 sessions ended early, and clotting scores did not differ ⁴. The UKKA suggests an initial heparin-free approach for these patients (2D) ²⁹, and KDIGO lists minimizing heparin among bleeding-reduction strategies ¹⁹. The signs of circuit clotting on a heparin-free run are dark streaks in the dialyzer, clot in the venous chamber, and rising venous or transmembrane pressure.

6.2 Access bleeding

Anticoagulation lengthens needle-site bleeding, but prolonged bleeding after needle removal is also a KDOQI clinical monitoring sign of access dysfunction ⁶⁷. Hold pressure without occluding flow, record minutes to hemostasis each session, and report a trend rather than attributing it to the blood thinner. The access pages in this module treat bleeding beyond the patient’s usual for three consecutive sessions as an outflow-stenosis signal: see Examining and cannulating the AVF/AVG and Catheter care, lock solutions, and bloodstream infection.

6.3 Gastrointestinal bleeding

Gastrointestinal bleeding is the commonest major bleed in dialysis (2.3 per 100 patient-years in DOPPS) ²⁴, and apixaban is associated with less of it than warfarin (OR 0.61) ¹⁰. An unexplained fall in hemoglobin or a rising ESA requirement is often the first sign; see Anemia: targets, ESAs, and hyporesponsiveness.

6.4 Timing, procedures, interactions, and reversal

• Apixaban does not need to be timed to dialysis. A session removes about 4% ¹², and exposure is independent of dialysis timing ⁶⁸. Doses are taken at the usual times on dialysis days, with no supplemental dose. A missed dose is taken the same day; never double ¹¹.
• Before procedures, the label advises holding apixaban at least 48 hours for moderate or high bleeding risk ¹¹, but modeling in hemodialysis patients found 48–72 hours insufficient to reach negligible levels ⁶⁸. Needle cannulation does not require a hold.
• Interactions. Strong combined P-gp and CYP3A4 inhibitors call for dose reduction or avoidance, and strong inducers should be avoided ¹¹. Adding a P2Y12 inhibitor to apixaban increased bleeding without reducing stroke or myocardial infarction ⁶⁹; the source review suggests stopping aspirin when an anticoagulant starts unless an acute coronary syndrome or recent stent requires it (2C).
• Reversal. Andexanet alfa reverses apixaban and rivaroxaban, idarucizumab reverses dabigatran, and prothrombin complex concentrate is used non-specifically ⁷⁰. Hemodialysis does not meaningfully remove apixaban ¹¹.

6.5 Falls

Older hemodialysis patients fall 1.60 times per person-year, with injury in 19% of falls ⁷¹. A pre-DOAC decision analysis found fall risk was not an important factor in choosing antithrombotic therapy ⁷², but subdural hematoma on hemodialysis carries 45.9% 1-year mortality, and 81% among patients previously on oral anticoagulants ⁷³. Count falls, prevent post-dialysis hypotension (see Intradialytic hypotension and dialysate cooling), and send any anticoagulated patient with a head strike for same-day imaging.

6.6 The dialysate bath

A 3 mEq/L rather than 2 mEq/L potassium bath was associated with about 14% lower incident AF in older incident patients ⁷⁴. In the ADAPT crossover trial, 3K plus sodium zirconium cyclosilicate on non-dialysis days lowered device-detected AF episodes versus 2K alone (rate ratio 0.52), though AF occurred in only 9 of 88 patients ⁷⁵. See Dialysate potassium: bath selection and the rule of 7 vs 8; beta-blocker choice is covered in Treating hypertension on dialysis.

7. A decision pathway

Figure 1 condenses sections 1 to 6 into the source review’s sequence of questions and grades. It is an evidence summary for shared decisions, not a unit protocol.

flowchart TD
    A["AF or flutter documented<br/>OFF dialysis: 12-lead ECG,<br/>or 30 s or more monitored"] --> B("Only brief, self-terminating<br/>AF during treatment?")
    B -- Yes --> B1["No anticoagulation for<br/>that alone - 2D<br/>Check K bath, UF rate,<br/>calcium, magnesium<br/>Repeat ECG off dialysis"]
    B -- No --> D("Score CHA2DS2-VASc.<br/>Any hard stop?<br/>Prior intracranial bleed;<br/>major bleed in 12 months<br/>without a fixed cause;<br/>recurrent GI bleed or<br/>angiodysplasia; platelets<br/>below 50,000; survival<br/>under 1 year; comfort care")
    D -- Yes --> E["LAAO evaluation - 2C<br/>if prior stroke or<br/>CHA2DS2-VASc 4 or more,<br/>survival over 2 years,<br/>and fit for TEE or CT and<br/>a short antiplatelet course.<br/>Otherwise no anticoagulation<br/>- 2C; revisit in 12 months"]
    D -- No --> F("CHA2DS2-VASc 2 or more<br/>in men, 3 or more<br/>in women?")
    F -- No --> F1["No anticoagulation;<br/>reassess yearly"]
    F -- Yes --> G("Prior ischemic stroke,<br/>TIA, or systemic<br/>embolism?")
    G -- Yes --> H["Anticoagulation<br/>favored - 2C"]
    G -- No --> I["EQUIPOISE - 2C<br/>Shared decision with<br/>numbers; an informed<br/>decline is valid"]
    I -- Declines --> X["Declines: no<br/>anticoagulation; revisit<br/>every 12 months"]
    I -- Accepts --> K
    H --> K("Warfarin required?<br/>Mechanical valve;<br/>moderate-severe<br/>rheumatic MS; active<br/>deceased-donor waitlist")
    K -- Yes --> K1["Warfarin, INR 2-3,<br/>drawn at the chair<br/>Reassess if TTR<br/>below 65%<br/>Stop if calciphylaxis"]
    K -- No --> L["Apixaban over<br/>warfarin - 2B<br/>Dose 2.5 vs 5 mg<br/>twice daily:<br/>EQUIPOISE - 2C<br/>Label: 2.5 mg if age 80+<br/>or weight 60 kg or less"]
    K1 --> M
    L --> M["Stop aspirin unless ACS<br/>or stent requires it - 2C<br/>Heparin-free start -<br/>UKKA 2D<br/>Watch hemoglobin,<br/>bleeding, and falls<br/>Re-decide every 12 months<br/>and after any bleed, head<br/>strike, admission, or<br/>new antiplatelet"]
    style H fill:#d3f9d8,stroke:#2f9e44,color:#000
    style I fill:#fff3bf,stroke:#f59f00,color:#000
    style L fill:#fff3bf,stroke:#f59f00,color:#000
    style E fill:#d0ebff,stroke:#1971c2,color:#000
    style X fill:#e9ecef,stroke:#868e96,color:#000
    style F1 fill:#e9ecef,stroke:#868e96,color:#000
    style B1 fill:#e9ecef,stroke:#868e96,color:#000

8. Lipid-lowering update

The statin evidence for dialysis, including the KDIGO 2013 positions and the negative 4D, AURORA, and SHARP-dialysis results, is on Cardiometabolic monitoring: lipids and statins, glycemic markers, and cardiovascular screening. This section adds what has been published since.

• No new randomized outcome trial. A PubMed title search of 2021–2026 records (71 hits, 26 September 2026) found no randomized cardiovascular outcome trial of a statin, ezetimibe, PCSK9 inhibitor, or inclisiran in dialysis. The nearest is a 14-patient, 12-week alirocumab study that lowered LDL cholesterol 45% with no clinical outcomes ⁷⁷.
• A target-trial emulation. In 3,019 statin-eligible Hong Kong patients with kidney failure, statin initiation was associated with fewer major cardiovascular events (intention-to-treat HR 0.78, 0.62–0.98) and a per-protocol ARR of 7% at 5 years (NNT approximately 14) ¹³. Dialysis-specific results were not reported, and a direction opposite to 4D and AURORA is the signature of healthy-user bias.
• Cohorts. All-comer cohorts report associations too large for a statin to explain (composite HR 0.51) ⁷⁸, or lower mortality without fewer cardiovascular events ⁷⁹. In established atherosclerotic disease, pooled mortality HRs were 0.85 and 0.94 ^14,15.

Evidence gaps

• No completed, adequately powered RCT of any anticoagulant against none in hemodialysis ^1,2.
• The apixaban dose has never been randomized in dialysis. SACK (2.5 mg) and SAFE-D2 (label dosing, mostly 5 mg) test different doses against no treatment, not against each other ².
• LAAO has no dialysis RCT result, and the best post-implant antiplatelet regimen in dialysis is unknown ^2,20,63.
• Heparin-free dialysis on DOACs rests on a 10-patient crossover trial of older oral anticoagulants ⁴.
• How much stroke in dialysis AF is actually caused by AF is uncertain, given competing mortality, thrice-weekly heparin, and non-cardioembolic mechanisms ^23,28.
• Current European guidance, the 2024 ESC AF guideline and the 2026 ESC/ERA guideline, was not read for the source review ^65,66.

At the chair

References

Adapted from the author’s canonical review Atrial Fibrillation and Anticoagulation in Maintenance Hemodialysis (reference-checked 2026-09-26; every journal reference matched to its PubMed record). Numbering is local to this page. Trial registrations are cited by NCT number; the apixaban label and the UK Kidney Association guideline have no PubMed record.

1. Harel Z, Smyth B, Badve SV, et al. Anticoagulation for patients with atrial fibrillation receiving dialysis: a pilot randomized controlled trial (SAFE-D). J Am Soc Nephrol. 2025;36(5):901-910. PMID: 39495569
2. ClinicalTrials.gov registry records, accessed 26 September 2026: NCT03987711 (SAFE-D); NCT02886962 (AVKDIAL); NCT03862859 (DANWARD); NCT07779746 (SAFE-D2); NCT05679024 (SACK); NCT06402851 (VISIONAIRE); NCT02942407 (RENAL-AF); NCT02039167 (WatchAFIB); NCT02885545 (STOP-HARM); NCT05204212 (LAA-KIDNEY). Registry records; no PubMed record.
3. Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial (RENAL-AF). Circulation. 2022;146(23):1735-1745. PMID: 36335914
4. Krummel T, Scheidt E, Borni-Duval C, et al. Haemodialysis in patients treated with oral anticoagulant: should we heparinize? Nephrol Dial Transplant. 2014;29(4):906-13. PMID: 24459138
5. Reinecke H, Engelbertz C, Bauersachs R, et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation. 2023;147(4):296-309. PMID: 36335915
6. Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580-4. PMID: 22121234
7. Galloway PA, El-Damanawi R, Bardsley V, et al. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. Nephron. 2015;129(3):197-201. PMID: 25720849
8. Brandenburg VM, Kramann R, Rothe H, et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant. 2017;32(1):126-132. PMID: 26908770
9. Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519-1529. PMID: 29954737
10. AlTurki A, Marafi M, Dawas A, et al. Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis. J Arrhythm. 2024;40(3):440-447. PMID: 38939758
11. ELIQUIS (apixaban) tablets, prescribing information. E.R. Squibb & Sons / Bristol-Myers Squibb. DailyMed structured product label, set ID e9481622-7cc6-418a-acb6-c5450daae9b0 (version published May 2025), sections 2.1, 2.3, 2.4, 2.6, 7.1–7.3, 8.6, 12.3. Regulatory label; no PubMed record.
12. Mavrakanas TA, Samer CF, Nessim SJ, et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28(7):2241-2248. PMID: 28302754
13. Cheng FWT, Xu W, Tang SCW, et al. Long-term benefits and safety of statins in patients with kidney failure: a target trial emulation study. J Am Soc Nephrol. 2025;36(5):882-889. PMID: 39480503
14. Elkoumi O, Elkoumi A, Elbairy MK, et al. Impact of statins on mortality and cardiovascular outcomes in dialysis patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Am J Cardiol. 2025;256:49-59. PMID: 40669550
15. Chienwichai K, Mongkolrattanakul P, Chang A, et al. Mortality and cardiovascular outcomes associated with statin use in dialysis patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Kidney Blood Press Res. 2026 (online ahead of print). PMID: 42700414
16. Zimmerman D, Sood MM, Rigatto C, et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012;27(10):3816-22. PMID: 23114904
17. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77(12):1098-106. PMID: 20054291
18. Roy-Chaudhury P, Tumlin JA, Koplan BA, et al. Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney Int. 2018;93(4):941-951. PMID: 29395340
19. Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018;39(24):2314-2325. PMID: 29522134
20. Genovesi S, Camm AJ, Covic A, et al. Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation (EuDial). Nephrol Dial Transplant. 2024;39(8):1248-1257. PMID: 38816212
21. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625-35. PMID: 22894575
22. Genovesi S, Vincenti A, Rossi E, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis. 2008;51(2):255-62. PMID: 18215703
23. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. PMID: 38033089
24. Coyle CR, Bash LD, Ramey DR, et al. Major bleeding rates in an international cohort of patients with end-stage kidney disease. Kidney Int Rep. 2024;9(9):2814-2818. PMID: 39291210
25. Guedes M, Andrews C, Zhao J, et al. Multinational real-world practice patterns in the use of antithrombotic therapy among patients on hemodialysis and peritoneal dialysis. Kidney Med. 2026;8(3):101211. PMID: 41675209
26. Langenhuijsen LFS, Derksen DCL, Milders J, et al. Systematic review and meta-analysis of the predictive performance of stroke and bleeding prediction models in atrial fibrillation patients with kidney disease. Kidney Med. 2026;8(2):101200. PMID: 41630994
27. Madken M, Mallick R, Rhodes E, et al. Development and validation of a predictive risk algorithm for bleeding in individuals on long-term hemodialysis: an international prospective cohort study (BLEED-HD). Can J Kidney Health Dis. 2023;10:20543581231169610. PMID: 37377481
28. De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. Nephrol Dial Transplant. 2022;37(11):2072-2079. PMID: 33647941
29. Parker K, Power A, et al. Clinical practice guideline: anticoagulation for atrial fibrillation in adults with advanced kidney disease. UK Kidney Association; final version September 2025, review date September 2028. Guideline document; no PubMed record.
30. Winkelmayer WC, Hu A, Khairallah P, et al. Oral anticoagulant initiation in patients with kidney failure on hemodialysis newly diagnosed with atrial fibrillation (2007-2020): an observational study of trends and disparities. Kidney Med. 2025;7(2):100926. PMID: 39844893
31. Chan KE, Lazarus JM, Thadhani R, et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223-33. PMID: 19713308
32. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129(11):1196-203. PMID: 24452752
33. Shen JI, Montez-Rath ME, Lenihan CR, et al. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2015;66(4):677-88. PMID: 26162653
34. Kai B, Bogorad Y, Nguyen LN, et al. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. Heart Rhythm. 2017;14(5):645-651. PMID: 28185918
35. Kim DG, Kim SH, Park SY, et al. Anticoagulation in patients with end-stage kidney disease and atrial fibrillation: a national population-based study. Clin Kidney J. 2024;17(2):sfae029. PMID: 38425706
36. Park SJ, Kim YN, Oh BK, et al. Efficacy and safety of antithrombotics in patients with atrial fibrillation undergoing hemodialysis: a nationwide cohort study in Korea. J Nephrol. 2025;38(8):2229-2237. PMID: 40745057
37. Mavrakanas TA, Garlo K, Charytan DM. Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clin J Am Soc Nephrol. 2020;15(8):1146-1154. PMID: 32444398
38. Winkelmayer WC, Erickson KF, Khairallah P, et al. Effectiveness and safety of apixaban initiation following newly-diagnosed atrial fibrillation in patients with kidney failure on hemodialysis. Am J Kidney Dis. 2026;87(3):313-323. PMID: 41352721
39. Randhawa MS, Vishwanath R, Rai MP, et al. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(4):e202175. PMID: 32250434
40. Kuno T, Takagi H, Ando T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol. 2020;75(3):273-285. PMID: 31976865
41. Kao TW, Chen ZW, Lin YH. Anticoagulation for patients with concomitant atrial fibrillation and end-stage renal disease: a systematic review and network meta-analysis. J Am Heart Assoc. 2024;13(8):e034176. PMID: 38606775
42. Du Y, Zeng Y, Xu S, et al. Oral anticoagulant therapy for patients with atrial fibrillation on long-term dialysis: a network meta-analysis of 137,574 patients. Eur J Clin Invest. 2025;55(12):e70120. PMID: 40919820
43. Hashimoto K, Fujisaki T, Aikawa T, et al. Optimal thromboembolism prevention for patients with atrial fibrillation on long-term dialysis. Pacing Clin Electrophysiol. 2025;48(7):733-753. PMID: 40468697
44. Genovesi S, Kuno T, Floege J, et al. Oral anticoagulation and left atrial appendage closure in dialysis atrial fibrillation: between stroke prevention and bleeding hazard. Clin Kidney J. 2026;19(7):sfag217. PMID: 42436946
45. Ballegaard ELF, Lindhard K, Lindhardt M, et al. Protocol for a randomised controlled trial comparing warfarin with no oral anticoagulation in patients with atrial fibrillation on chronic dialysis: the Danish Warfarin-Dialysis (DANWARD) trial. BMJ Open. 2024;14(2):e081961. PMID: 38413147
46. De Vriese AS, Caluwé R, Van Der Meersch H, et al. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol. 2021;32(6):1474-1483. PMID: 33753537
47. Chang TY, Chan YH, Chao TF, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation and kidney failure under hemodialysis: a meta-analysis of controlled randomized trials. J Arrhythm. 2025;41(3):e70094. PMID: 40390785
48. Shaheen O, Hamdy M, Afifi IA, et al. Direct oral anticoagulants versus vitamin K antagonists for atrial fibrillation patients on dialysis: a systematic review and meta-analysis of randomized controlled trials and real-world evidence. J Thromb Thrombolysis. 2026 (online ahead of print). PMID: 42177744
49. Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):628-36. PMID: 26331581
50. Xu Y, Chang AR, Inker LA, et al. Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. Circulation. 2023;148(19):1445-1454. PMID: 37681341
51. Yang SH. Apixaban dose selection in kidney failure: reconciling pharmacokinetics and clinical outcomes. Ann Pharmacother. 2026 (online ahead of print). PMID: 42670022
52. Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131(11):972-9. PMID: 25595139
53. De Vriese AS, Caluwé R, Bailleul E, et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis. 2015;66(1):91-8. PMID: 25804678
54. Parasrampuria DA, Marbury T, Matsushima N, et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost. 2015;113(4):719-27. PMID: 25566930
55. Quinn LM, Richardson R, Cameron KJ, et al. Evaluating time in therapeutic range for hemodialysis patients taking warfarin. Clin Nephrol. 2015;83(2):80-5. PMID: 25500296
56. Yang F, Hellyer JA, Than C, et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2017;103(11):818-826. PMID: 27852694
57. De Vriese AS, Caluwé R, Pyfferoen L, et al. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie study. J Am Soc Nephrol. 2020;31(1):186-196. PMID: 31704740
58. Kaisaier W, Xu Z, Guo L, et al. Left atrial appendage closure vs oral anticoagulation for stroke prevention in atrial fibrillation: long-term outcomes from 4 randomized trials. Heart Rhythm. 2025;22(11):e1086-e1096. PMID: 40754231
59. Doshi SK, Kar S, Nair DG, et al. Left atrial appendage closure or anticoagulation for atrial fibrillation (CHAMPION-AF). N Engl J Med. 2026;394(21):2083-2094. PMID: 41910347
60. Genovesi S, Porcu L, Rebora P, et al. Long-term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open label, observational study. Clin Kidney J. 2023;16(12):2683-2692. PMID: 38046009
61. Dhar G, Phadnis MA, Hunt SL, et al. Left atrial appendage occlusion vs anticoagulants in dialysis with atrial fibrillation. JAMA Netw Open. 2025;8(9):e2530990. PMID: 40924421
62. Gill GS, Shailly S, Chakrala T, et al. Adverse outcomes with left atrial appendage occlusion device implantation in chronic and end stage kidney disease: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2025;75:56-63. PMID: 39191612
63. Saraei R, Heine GH, Osmancik P, et al. Left atrial appendage closure in patients with non-valvular atrial fibrillation and end stage chronic KIDNEY disease: rationale and design of the prospective randomized LAA-KIDNEY trial. Am Heart J. 2026;300:107474. PMID: 42107551
64. Genovesi S, Regolisti G, Ferraro PM, et al. Thromboembolic prophylaxis in kidney failure patients with atrial fibrillation undergoing hemodialysis: from risk stratification to decision making on anticoagulants or left atrial appendage closure. A position paper endorsed by the Italian Society of Nephrology. J Nephrol. 2026 (online ahead of print). PMID: 42642036
65. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. PMID: 39210723
66. Damman K, Ter Maaten JM, Mayne KJ, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J. 2026 (online ahead of print). PMID: 42661426
67. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164. PMID: 32778223
68. Konecki C, Lipman ML, Mavrakanas TA, et al. Population pharmacokinetic modelling of apixaban in end-stage kidney disease patients with atrial fibrillation receiving haemodialysis. Clin Pharmacokinet. 2025;64(2):307-321. PMID: 39853633
69. Mavrakanas TA, Charytan DM. Apixaban versus no anticoagulation by P2Y12 inhibitor prescription status in dialysis patients with atrial fibrillation. Kidney360. 2022;3(10):1769-1771. PMID: 36514740
70. Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. Am J Hematol. 2019;94(6):697-709. PMID: 30916798
71. Cook WL, Tomlinson G, Donaldson M, et al. Falls and fall-related injuries in older dialysis patients. Clin J Am Soc Nephrol. 2006;1(6):1197-204. PMID: 17699348
72. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677-85. PMID: 10218746
73. Yang L, Li Z, Dai X, et al. Nontraumatic subdural hematoma in patients on hemodialysis with end-stage kidney disease: a systematic review and pooled analysis. Front Neurol. 2023;14:1251652. PMID: 37789893
74. Hu A, Liu S, Montez-Rath ME, et al. Associations of serum and dialysate potassium concentrations with incident atrial fibrillation in a cohort study of older US persons initiating hemodialysis for kidney failure. Kidney Int Rep. 2023;8(2):305-316. PMID: 36815107
75. Charytan DM, Winkelmayer WC, Granger CB, et al. Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia (ADAPT). Kidney Int. 2025;107(1):169-179. PMID: 39490411
76. Genovesi S, Rebora P, Gallieni M, et al. Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study. J Nephrol. 2017;30(4):573-581. PMID: 27834042
77. East C, Bass K, Mehta A, et al. Alirocumab and lipid levels, inflammatory biomarkers, metabolomics, and safety in patients receiving maintenance dialysis: the ALIrocumab in DIALysis Study. Kidney Med. 2022;4(7):100483. PMID: 35801187
78. Baik M, Jeon J, Yoo J, et al. Effect of statins in patients with hemodialysis-dependent chronic kidney disease: a nationwide cohort study. J Am Heart Assoc. 2025;14(20):e043214. PMID: 41120813
79. Kim JE, Park S, Kim MS, et al. Statin initiation and all-cause mortality in incident statin-naïve dialysis patients. Atherosclerosis. 2021;337:59-65. PMID: 34429195
80. Damianaki A, Stambolliu E, Iliakis P, et al. Injectable lipid-lowering therapies in advanced chronic kidney disease: efficacy, safety and the dialysis paradox. Cardiovasc Drugs Ther. 2026 (online ahead of print). PMID: 42603236
81. Lee M, Choi WJ, Lee Y, et al. Association between statin therapy and mortality in patients on dialysis after atherosclerotic cardiovascular diseases. Sci Rep. 2023;13(1):10940. PMID: 37414847
82. Lo HY, Lin YS, Lin DS, et al. Association of statin therapy with major adverse cardiovascular and limb outcomes in patients with end-stage kidney disease and peripheral artery disease receiving maintenance dialysis. JAMA Netw Open. 2022;5(9):e2229706. PMID: 36048442
83. Yen CL, Fan PC, Chen JJ, et al. The benefit of LDL-C levels below 55 mg/dL in ESKD patients under statin treatment: a target trial emulation study. Atherosclerosis. 2026;421:121883. PMID: 42685616

Also in this module

• Dialysate potassium: bath selection and the rule of 7 vs 8
• Cardiometabolic monitoring: lipids and statins, glycemic markers, CV screening
• Examining and cannulating the AVF/AVG
• Catheter care, lock solutions, and bloodstream infection
• Anemia: targets, ESAs, and hyporesponsiveness
• Treating hypertension on dialysis: targets, trials, agents, dose timing
• Intradialytic hypotension and dialysate cooling
• Maintenance Hemodialysis — module index